Expression of Opioid Growth Factor,Opioid Growth Factor Receptor,P16,and P21 and Their Correlations With Clinicopathological Characteristics in Elderly Patients With Colorectal Cancer

Zeyu WANG, Benchang ZHANG, Hao ZHANG, Yixuan ZHANG, Xueliang WU, Yu WANG, Tingting QIAO, Xiuqing HAO, Juan YAN

Acta Academiae Medicinae Sinicae ›› 2025, Vol. 47 ›› Issue (6) : 896-909.

PDF(4521 KB)
Home Journals Acta Academiae Medicinae Sinicae
Acta Academiae Medicinae Sinicae

Abbreviation (ISO4): Acta Academiae Medicinae Sinicae      Editor in chief: Xuetao CAO

About  /  Aim & scope  /  Editorial board  /  Indexed  /  Contact  / 
PDF(4521 KB)
Acta Academiae Medicinae Sinicae ›› 2025, Vol. 47 ›› Issue (6) : 896-909. DOI: 10.3881/j.issn.1000-503X.16518
Original Articles

Expression of Opioid Growth Factor,Opioid Growth Factor Receptor,P16,and P21 and Their Correlations With Clinicopathological Characteristics in Elderly Patients With Colorectal Cancer

Author information +
History +

Abstract

Objective To investigate the expression of opioid growth factor(OGF),OGF receptor(OGFR),P16,and P21 in elderly patients with colorectal cancer and their correlations with clinicopathological characteristics. Methods Bioinformatic analysis of OGFR was performed via differential expression analysis,survival analysis,single-cell RNA sequencing,and spatial transcriptomics.A total of 167 elderly patients with colorectal cancer were enrolled,with 30 fresh tissue samples collected from January 2023 to December 2024 and 137 paraffin-embedded tissue samples collected from January 2016 to January 2020.All the specimens were collected from confirmed cases at the First Affiliated Hospital of Hebei North University.OGF expression in the 30 fresh tissue samples was detected by ELISA,while the protein levels of OGFR,P16,and P21 were measured by Western blot.Immunohistochemistry was employed to assess OGFR,P16,and P21 expression in the 137 paraffin-embedded samples.SPSS 20.0 was used to analyze the correlations of OGFR,P16,and P21 expression with clinicopathological characteristics.The Spearman method was adopted to evaluate correlations among OGFR,P16,and P21 expression.Overall 5-year survival and differences between groups were assessed by Kaplan-Meier survival curves and the log-rank test. Results Differential expression analysis revealed that the expression of OGFR was upregulated in colorectal cancer tissue samples(P<0.001).Survival analysis revealed a significant correlation between high OGFR expression and poor prognosis(disease-free interval:P=0.019,disease-specific survival:P=0.015).Single-cell and spatial omics analyses indicated that OGFR was primarily expressed in tumor cells.ELISA results showed that compared with that in the adjacent normal tissue,the OGF expression levels elevated in pathological stages Ⅰ(P<0.001),Ⅱ(P=0.042),Ⅲ(P<0.001),and Ⅳ(P=0.001).Western blot results demonstrated that compared with that in the adjacent normal tissue,the protein level of OGFR was up-regulated in pathological stages Ⅰ(P<0.001),Ⅱ(P=0.047),Ⅲ(P=0.045),and Ⅳ(P=0.012).Compared with those in the adjacent normal tissue,the protein levels of P16 and P21 were down-regulated in pathological stages Ⅰ(P=0.001,P<0.001),Ⅱ(P=0.031,P=0.008),Ⅲ(P=0.026,P=0.024),and Ⅳ(P=0.018,P=0.015).Immunohistochemistry results demonstrated that OGFR had higher expression in cancer tissue samples than in adjacent normal tissue samples(P<0.001),and its expression level was correlated with T stage(P=0.047),lymph node metastasis(P=0.035),TNM stage(P=0.013),differentiation degree(P=0.043),and distant metastasis(P=0.030).Conversely,the protein levels of P16 and P21 were lower in cancer tissue samples(all P<0.001).P16 expression was correlated with T stage(P=0.009),lymph node metastasis(P=0.035),TNM stage(P=0.001),and differentiation degree(P=0.021).P21 expression showed correlations with T stage(P=0.009),lymph node metastasis(P=0.002),and TNM stage(P=0.046).The 5-year overall survival rate of the 137 elderly patients with colorectal cancer was 55.47%.The patients with positive expression of OGFR had a lower 5-year overall survival rate than those with negative expression(P=0.001).The patients with negative expression of P16 or P21 had a lower 5-year overall survival rate than those with positive expression(P16:P<0.001;P21:P=0.007). Conclusions In the colorectal cancer tissue of elderly patients,the expression of OGFR was negatively correlated with that of P16 and P21.The OGF-OGFR signaling pathway may promote colorectal cancer progression by suppressing P16 and P21 expression.The combined detection of these markers shows potential as a valuable reference for assessing disease progression.

Key words

opioid growth factor / opioid growth factor receptor / colorectal cancer / P16 / P21

Cite this article

Download Citations
Zeyu WANG , Benchang ZHANG , Hao ZHANG , et al . Expression of Opioid Growth Factor,Opioid Growth Factor Receptor,P16,and P21 and Their Correlations With Clinicopathological Characteristics in Elderly Patients With Colorectal Cancer[J]. Acta Academiae Medicinae Sinicae. 2025, 47(6): 896-909 https://doi.org/10.3881/j.issn.1000-503X.16518

References

[1]
Ma YK, Qu L, Chen N, et al. Effect of multimodal opioid-sparing anesthesia on intestinal function and prognosis of elderly patients with hypertension after colorectal cancer surgery[J]. BMC Surg, 2024, 24(1):341.DOI:10.1186/s12893-024-02604-y.
[2]
Lee MS, Chiou SY, Hsu FC, et al. The effectiveness of 23-valent pneumococcal polysaccharide vaccine on elderly colorectal cancer long-term survivors:a population-based exact-matched cohort study[J]. Hum Vaccin Immunother, 2024, 20(1):2350093.DOI:10.1080/21645515.2024.2350093.
[3]
Janeczek M, Plewniok J, Partyka M, et al. Molecular mechanisms of resistance and new therapeutic approaches in the treatment of colorectal cancer-a review of the literature[J]. J Educ Health Sport, 2024, 66:55620.DOI:10.12775/jehs.2024.66.55620.
[4]
Wang R, Zhang Y, Shan F. Interaction of opioid growth factor(OGF) and opioid antagonist and their significance in cancer therapy[J]. Int Immunopharmacol, 2019, 75:105785.DOI:10.1016/j.intimp.2019.105785.
[5]
Ciwun M, Tankiewicz-Kwedlo A, Pawlak D. Low-dose naltrexone as an adjuvant in combined anticancer therapy[J]. Cancers(Basel), 2024, 16(6):1240.DOI:10.3390/cancers16061240.
[6]
Chen X, Jian D, Xing J, et al. Targeting OGF/OGFR signal to mitigate doxorubicin-induced cardiotoxicity[J]. Free Radic Biol Med, 2024, 223:398-412.DOI:10.1016/j.freeradbiomed.2024.08.005.
[7]
Budka J, Debowski D, Mai S, et al. Design,synthesis, and antitumor evaluation of an opioid growth factor bioconjugate targeting pancreatic ductal adenocarcinoma[J]. Pharmaceutics, 2024, 16(2):283.DOI:10.3390/pharmaceutics16020283.
[8]
Huang H, Wang X, Zhang S, et al. In vitro and in vivo killing effects of methionine enkephalin on osteosarcoma[J]. Int Immunopharmacol, 2023, 125(Pt B):111226.DOI:10.1016/j.intimp.2023.111226.
[9]
Vecera L, Prasil P, Srovnal J, et al. Morphine analgesia,cannabinoid receptor 2,and opioid growth factor receptor cancer tissue expression improve survival after pancreatic cancer surgery[J]. Cancers(Basel), 2023, 15(16):4038.DOI:10.3390/cancers15164038.
[10]
Qu N, Wang C, Meng Y, et al. Superior anticancer potential of nano-paclitaxel combined bevacizumab treatment in ovarian cancer[J]. Curr Pharm Biotechnol, 2023, 24(9):1204-1212.DOI:10.2174/1389201023666221011115301.
[11]
Ma Y, Yi C, Cai N, et al. Integration of single-cell and spatial transcriptome sequencing identifies CDKN2A as a senescent biomarker in endothelial cells implicating hepatocellular carcinoma malignancy[J]. J Cancer Res Clin Oncol, 2024, 150(11):487.DOI:10.1007/s00432-024-06017-5.
[12]
Na JM, Kim HS. Comprehensive clinicopathological and immunohistochemical analysis of human papillomavirus-independent squamous cell carcinoma and adenosquamous carcinoma of the uterine cervix[J]. Anticancer Res, 2024, 44(11):4969-4981.DOI:10.21873/anticanres.17322.
[13]
Hu F, Zhao L, Wang J, et al. TRIM40 interacts with ROCK1 directly and inhibits colorectal cancer cell proliferation through the c-Myc/p21 axis[J]. Biochim Biophys Acta Mol Cell Res, 2024, 1871(8): 119855.DOI:10.1016/j.bbamcr.2024.119855.
[14]
Choschzick M, Gut A, Hoesli L, et al. Role of immunohistochemical analysis of p16 and p53 in vulvar carcinoma[J]. Int J Gynecol Pathol, 2024, 44:(4): 308-313. DOI: 10.1097/PGP.0000000000001077.
[15]
Amano Y, Hasegawa M, Kihara A, et al. Clinicopathological and prognostic significance of stromal p16 and p53 expression in oral squamous cell carcinoma[J]. Ann Diagn Pathol, 2025, 75:152439.DOI:10.1016/j.anndiagpath.2025.152439.
[16]
Xie X, Macknight HP, Lu AL, et al. RNA splicing variants of the novel long non-coding RNA,CyKILR,possess divergent biological functions in non-small cell lung cancer[J]. Mol Ther Nucleic Acids, 2024, 36(1):102412.DOI:10.1016/j.omtn.2024.102412.
[17]
Naz F, Tanveer N, Verma H, et al. Histomorphology based prediction of p16 immunopositivity and p16/HPV DNA co-positivity in oral squamous cell carcinoma[J]. Ann Diagn Pathol, 2024, 73:152389.DOI:10.1016/j.anndiagpath.2024.152389.
[18]
Mishima M, Takai A, Takeda H, et al. TERT upregulation promotes cell proliferation via degradation of p21 and increases carcinogenic potential[J]. J Pathol, 2024, 264(3):318-331.DOI:10.1002/path.6351.
[19]
Thangavelu L, Altamimi ASA, Ghaboura N, et al. Targeting the p53-p21 axis in liver cancer:linking cellular senescence to tumor suppression and progression[J]. Pathol Res Pract, 2024, 263:155652.DOI:10.1016/j.prp.2024.155652.
[20]
Park S, Kim S, Kim MY, et al. Pituitary tumor-transforming gene 1 regulates the senescence and apoptosis of oral squamous cell carcinoma in a p21-dependent DNA damage response manner[J]. Oncol Rep, 2024, 52(4):135.DOI:10.3892/or.2024.8794.
[21]
Wu Y, Yang S, Ma J, et al. Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level[J]. Cancer Discov, 2022, 12(1):134-153.DOI:10.1158/2159-8290.CD-21-0316.
[22]
Amin MB, Greene FL, Edge SB, et al. AJCC cancer staging manual[M]. 8th ed.Berlin: Springer, 2017:216-236.
[23]
Siegel RL, Wagle NS, Cercek A, et al. Colorectal cancer statistics,2023[J]. CA Cancer J Clin, 2023, 73(3):233-254.DOI:10.3322/caac.21772.
[24]
王少明, 郑荣寿, 韩冰峰, 等. 2022年中国人群恶性肿瘤发病与死亡年龄特征分析[J]. 中国肿瘤, 2024, 33(3):165-174.DOI:10.11735/j.issn.1004-0242.2024.03.A001.
[25]
Qu N, Wang X, Meng Y, et al. Prospective oncotarget for gynecological cancer:opioid growth factor(OGF)-opioid growth factor receptor(OGFr) axis[J]. Int Immunopharmacol, 2019, 75:105723.DOI:10.1016/j.intimp.2019.105723.
[26]
Cheng F, McLaughlin PJ, Verderame MF, et al. The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation[J]. Mol Biol Cell, 2009, 20(1):319-327.DOI:10.1091/mbc.E08-07-0681.
[27]
Wang X, Li S, Yan S, et al. Methionine enkephalin inhibits colorectal cancer by remodeling the immune status of the tumor microenvironment[J]. Int Immunopharmacol, 2022, 111:109125.DOI:10.1016/j.intimp.2022.109125.
[28]
Belltall A, Mazzinari G, Garrido-Cano I, et al. Opioid receptor expression in colorectal cancer:a nested matched case-control study[J]. Front Oncol, 2022, 12:801714.DOI:10.3389/fonc.2022.801714.
[29]
Zagon IS, Donahue RN, Rogosnitzky M, et al. Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function[J]. Exp Biol Med, 2008, 233(8):968-979.DOI:10.3181/0802-RM-58.
[30]
Szatmari T, Mocan S, Neagos CM, et al. Biomarker profiles and clinicopathological features in head and neck squamous cell carcinoma atients[J]. Medicina(Kaunas), 2024, 60(10):1681.DOI:10.3390/medicina60101681.
PDF(4521 KB)

Accesses

Citation

Detail

Sections
Recommended

/